SS-31, also called elamipretide, is a synthetic tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) that binds cardiolipin on the inner mitochondrial membrane. Unlike most peptides, it doesn't work through a receptor — it stabilizes the structural scaffold that powers every cell.
Research-context information only. SS-31 is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
That mechanism matters because mitochondrial dysfunction sits underneath almost every chronic disease of aging: heart failure, sarcopenia, cognitive decline, macular degeneration, and metabolic disease. SS-31 is the most thoroughly studied peptide targeting that layer.
Below are the 7 benefits with the strongest evidence — ranked by quality of data, not by hype. Several have human clinical trial support. Some failed their primary endpoints but showed mechanistic benefit. We'll be clear about which is which.
How SS-31 Works (30-Second Version)
Cardiolipin is a phospholipid found only on the inner mitochondrial membrane. It anchors cytochrome c, organizes the electron transport chain into supercomplexes, and shapes the cristae folds where ATP is produced. When cardiolipin is peroxidized or disorganized — by age, ischemia, or genetic mutation — mitochondria leak electrons, produce less ATP, and pump out more reactive oxygen species.
SS-31 binds cardiolipin via electrostatic and hydrophobic interactions (Szeto 2014). This stabilizes cristae structure, restores electron flow, and increases ATP output — usually within an hour of dosing. For the mechanism deep-dive see the SS-31 research guide; for protocol specifics see the SS-31 dosing guide.
Benefit 1: Rapid Restoration of Mitochondrial ATP Output
Evidence quality: Strong (human RCT)
This is the signature finding. In a randomized, double-blind, placebo-controlled trial of 39 older adults (60-85) pre-screened for mitochondrial dysfunction, a single IV dose of elamipretide significantly raised in vivo mitochondrial ATPmax in skeletal muscle — measured non-invasively via magnetic resonance spectroscopy (Roshanravan et al., 2021).
The effect rose on the day of dosing and faded by day 7, consistent with the 16-hour plasma half-life. For comparison, achieving similar ATPmax improvements through exercise training takes weeks to months.
Why it matters: ATP is the universal energy currency. If you can measurably raise it in vivo — in human muscle — after a single dose, every downstream benefit (recovery, endurance, cellular resilience) has a plausible mechanistic basis.
Benefit 2: Cardiac Function in Cardiolipin Deficiency (Barth Syndrome)
Evidence quality: Strong (Phase 2/3 RCT + 168-week extension, FDA approved 2025)
Barth syndrome is a rare X-linked genetic disorder causing defective cardiolipin remodeling, leading to cardiomyopathy, skeletal myopathy, and neutropenia. The TAZPOWER trial randomized 12 subjects to 40 mg/day SC elamipretide vs placebo for 12 weeks, followed by crossover and open-label extension (Thompson et al., 2021).
The 12-week primary endpoints (6-minute walk test and symptom assessment) were not met. But the 168-week open-label extension showed sustained improvement in cardiac function, exercise capacity, and quality of life — strong enough that the FDA approved elamipretide for Barth syndrome in September 2025. Eight of the original 10 open-label subjects reached the 168-week visit.
This is the single cleanest proof that cardiolipin binding translates to clinical benefit in humans — because Barth patients have the underlying cardiolipin defect SS-31 is designed to address.
Benefit 3: Reversal of Age-Related Skeletal Muscle Dysfunction
Evidence quality: Strong (preclinical, consistent across multiple labs)
In aged mice, a single hour of SS-31 treatment restored in vivo P/O ratio and ATPmax to young-adult levels (Siegel et al., 2013). Eight days of treatment increased whole-animal treadmill endurance.
A follow-up study confirmed SS-31 reverses redox proteome damage across aged skeletal muscle — hundreds of cysteine residues lose pathological S-glutathionylation, gastrocnemius mass and fatigue resistance improve, and exercise tolerance increases without any change in mitochondrial content (Campbell et al., 2019).
Most recently, SS-31 was shown to bind directly to the adenine nucleotide translocator (ANT) and improve ADP sensitivity in aged human muscle mitochondria within an hour (Siegel et al., 2023) — giving a molecular explanation for the rapid functional rescue.
Caveat: the mouse data are strong, and the human muscle ex vivo + single-dose ATP data support the mechanism, but long-term RCTs of SS-31 for age-related sarcopenia have not been run.
Benefit 4: Slower Retinal Degradation in Dry AMD
Evidence quality: Moderate (Phase 2 RCT, primary endpoint missed)
The ReCLAIM-2 Phase 2 trial tested 40 mg/day SC elamipretide for 48 weeks in geographic atrophy secondary to AMD (Allingham et al., 2024). Primary endpoints (best-corrected visual acuity, low-luminance BCVA change) were not met.
Exploratory secondary analyses showed slower ellipsoid zone degradation — the retinal layer most tied to photoreceptor survival. Stealth is using ellipsoid zone preservation as the primary endpoint for the Phase 3 AMD program.
The earlier Phase 1 ReCLAIM study (n=15 completers, 24 weeks) showed mean +4.6 letter BCVA improvement and +5.4 letters on low-luminance BCVA (Cousins et al., 2022).
Translation: the mechanism looks real at the tissue level, but functional vision benefit hasn't cleared a regulatory endpoint yet.
Ready to buy? Compare verified vendors on our best SS-31 sources page, or browse all coupon codes for up to 50% off.
